不同剂量降纤酶治疗进展性脑梗死疗效观察

Assessment of defibrase of different doses in treatment of acute progressive cerebral infarction

目的 :观察不同剂量降纤酶治疗急性进展型脑梗死的疗效。方法 :将 10 0例急性进展型脑梗死患者随机分为大剂量降纤酶治疗组 ,常规剂量治疗组 ,和对照组。大剂量治疗组首次剂量 2 0u静滴 ,以后每天 10u静滴 ,连用 7d ;常规剂量治疗组首剂量降纤酶 10u ,第 2 ,3次剂量均为 5u ,上述两组均在发病 2 4h内开始治疗。对照组则每天静滴川芎嗪 3支 ,连用 2周。评定的终点指标包括脑卒中的临床神经功能缺损程度评分 ,血浆纤维蛋白原 (FIB)水平测定等。结果 :①与对照组比较 ,不同剂量降纤酶治疗后血浆水平均明显下降 (P <0 .0 1) ;②治疗 2周后神经功能缺损程度评分 ,大剂量降纤酶治疗组与对照组比较有显著差异 (P <0 .0 1)。结论

Objective: To assess the efficacy of defibrase with different doses in the treatment of acute progressive cerebral infarction. Method: 100 cases with acute progressive cerebral infarction were allocated to receive either an initial intravenous infusion of defibrase 20u,and then 10u each day for 10 days continuously;or 10u first,5u each day for the subsequent two days;and for the control group, placebo was given continuously each day for two weeks.The end points included Clinically Neurological Deficits Scale of Stroke and the level of plasma fibrinogen(FIB),etc. Result: ①The level of plasma fibrinogen in defibrase groups was remarkably declined after treatment(P<0.01); ②there were significant differences at Clinically Neurological Deficits Scale of Stroke at 2 weeks only between the large dose group and control group(P<0.01).Conclusion: The efficacy of large dose defibrase is significant in the treatment of acute progressive cerebral infarction.